These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Detection of skeletal muscle metastasis: torso FDG PET-CT versus contrast-enhanced chest or abdomen CT. So Y; Yi JG; Song I; Lee WW; Chung HW; Park JH; Moon SG Acta Radiol; 2015 Jul; 56(7):860-6. PubMed ID: 25406434 [TBL] [Abstract][Full Text] [Related]
5. Polysplenia Syndrome With Splenic and Skeletal Muscle Metastases From Thyroid Carcinoma Evaluated by FDG PET/CT: Case Report and Literature Review: A Care-Compliant Article. Li ZG; Lin ZC; Mu HY Medicine (Baltimore); 2016 Jan; 95(4):e2532. PubMed ID: 26825891 [TBL] [Abstract][Full Text] [Related]
6. Low positive yield from routine inclusion of the brain in whole-body 18F-FDG PET/CT imaging for noncerebral malignancies: results from a large population study. Manohar K; Bhattacharya A; Mittal BR Nucl Med Commun; 2013 Jun; 34(6):540-3. PubMed ID: 23503001 [TBL] [Abstract][Full Text] [Related]
7. Multiple muscle metastases from lung cancer detected by FDG PET/CT. Yilmaz M; Elboga U; Celen Z; Isik F; Tutar E Clin Nucl Med; 2011 Mar; 36(3):245-7. PubMed ID: 21285692 [TBL] [Abstract][Full Text] [Related]
8. Intramuscular metastases on FDG PET-CT: a review of the literature. Emmering J; Vogel WV; Stokkel MP Nucl Med Commun; 2012 Feb; 33(2):117-20. PubMed ID: 22124361 [TBL] [Abstract][Full Text] [Related]
9. FDG-PET/CT assessment of differential chemotherapy effects upon skeletal muscle metabolism in patients with melanoma. Goncalves MD; Alavi A; Torigian DA Ann Nucl Med; 2014 May; 28(4):386-92. PubMed ID: 24562913 [TBL] [Abstract][Full Text] [Related]
10. Focal fluorine-18 fluorodeoxyglucose-avid lesions without computed tomography correlate at whole-body positron emission tomography-computed tomography in oncology patients: how often are they malignant? Kumar R; Hawkins RA; Yeh BM; Wang ZJ Nucl Med Commun; 2011 Sep; 32(9):802-7. PubMed ID: 21685821 [TBL] [Abstract][Full Text] [Related]
11. Fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) for the detection of skeletal muscle and skin metastases in uterine leiomyosarcoma: a case report. Ozdemir E; Poyraz NY; Uzun B; Türkölmez S Rev Esp Med Nucl Imagen Mol; 2013; 32(4):257-9. PubMed ID: 23153988 [TBL] [Abstract][Full Text] [Related]
12. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle. Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129 [TBL] [Abstract][Full Text] [Related]
13. Incremental value of 18F-FDG PET/CT in therapeutic decision-making of potentially curable esophageal adenocarcinoma. Purandare NC; Pramesh CS; Karimundackal G; Jiwnani S; Agrawal A; Shah S; Kulkarni M; Laskar SG; Rangarajan V Nucl Med Commun; 2014 Aug; 35(8):864-9. PubMed ID: 24751701 [TBL] [Abstract][Full Text] [Related]
14. Early bone marrow metastasis detection: the additional value of FDG-PET/CT vs. CT imaging. Evangelista L; Panunzio A; Polverosi R; Ferretti A; Chondrogiannis S; Pomerri F; Rubello D; Muzzio PC Biomed Pharmacother; 2012 Sep; 66(6):448-53. PubMed ID: 22902054 [TBL] [Abstract][Full Text] [Related]
15. Clinical impact of "true whole-body" (18)F-FDG PET/CT: lesion frequency and added benefit in distal lower extremities. Kawata S; Imaizumi M; Kako Y; Oku N Ann Nucl Med; 2014 May; 28(4):322-8. PubMed ID: 24488705 [TBL] [Abstract][Full Text] [Related]
16. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities. Salem SS; Shahin MA Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387 [TBL] [Abstract][Full Text] [Related]
17. Supplemental value of diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) technique to whole-body magnetic resonance imaging in detection of bone metastases from thyroid cancer. Sakurai Y; Kawai H; Iwano S; Ito S; Ogawa H; Naganawa S J Med Imaging Radiat Oncol; 2013 Jun; 57(3):297-305. PubMed ID: 23721138 [TBL] [Abstract][Full Text] [Related]
18. Clinical value of whole-body F-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with carcinoma of unknown primary. Wang G; Wu Y; Zhang W; Li J; Wu P; Xie C J Med Imaging Radiat Oncol; 2013 Feb; 57(1):65-71. PubMed ID: 23374557 [TBL] [Abstract][Full Text] [Related]
19. Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan? Bannas P; Derlin T; Groth M; Apostolova I; Adam G; Mester J; Klutmann S Ann Nucl Med; 2012 Jan; 26(1):77-85. PubMed ID: 22006540 [TBL] [Abstract][Full Text] [Related]
20. Multiple distant muscular metastases from non-small cell lung carcinoma evidenced by 18F-FDG PET/CT. Caobelli F; Pizzocaro C; Guerra UP Rev Esp Med Nucl Imagen Mol; 2013; 32(5):338-9. PubMed ID: 23809515 [No Abstract] [Full Text] [Related] [Next] [New Search]